The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...
Study looks at benefits and risks to popular weight-loss drugs; Kentucky leads nation in use of them
By Melissa Patrick and Liberty Gilbert Kentucky Health News Whether it is prescribed for diabetes or weight loss, Ozempic and ...
SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.
Hosted on MSN1d
GLP-1RA developer Metsera targets $289m IPOMetsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...
Whether it is prescribed for diabetes or weight loss, Ozempic and other weight loss drugs have found their home in Kentucky, even though researchers from Washington University in St. Louis ...
Ozempic and other weight loss drugs have found their home in Kentucky, even though researchers from Washington University in ...
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...
Whether it is prescribed for diabetes or weight loss, Ozempic and other weight loss drugs have found their home in Kentucky, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback